MAO-B inhibitors in Parkinson's disease.
Olanow
C W
CW
Department of Neurology, University of South Florida, Tampa 33606.
D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008995:Monoamine Oxidase / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D011954:Receptors, Dopamine; D012642:Selegiline; D007980:Levodopa; D008995:Monoamine Oxidase